Search results for "81"

showing 10 items of 2468 documents

Immune-inflammatory responses in the elderly: An update

2018

EDITORIAL NO ABSTRACT

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyAgingAllergyImmunestimulationImmunosenescenceImmunologyMEDLINEClinical nutritionlcsh:Geriatrics03 medical and health sciencesImmune systemElderlymedicineCancerInflammationbiologybusiness.industryPublic healthVaccinationCancerImmunosenescencemedicine.diseaseVaccinationlcsh:RC952-954.6030104 developmental biologyEditorialImmunologybiology.proteinAntibodybusinesslcsh:RC581-607
researchProduct

Genetics of exceptional longevity: possible role of GM allotypes

2018

NOT REQUESTED FOR COMMENTARIES

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyAgingmedia_common.quotation_subjectImmunologyLongevityGenome-wide association studyClinical nutritionBiologylcsh:GeriatricsCase control studies03 medical and health sciencesCase control studies; GM allotypes; GWAS; Immune response; Longevity; Immunology; Aging0302 clinical medicinemedicineGWASCase control studieImmune responsemedia_commonGeneticsGM allotypeSettore MED/04 - Patologia GeneraleGeriatrics gerontologyPublic healthLongevitylcsh:RC952-954.6030104 developmental biologyCommentaryGM allotypesGm Allotypeslcsh:RC581-607030215 immunologyImmunity & Ageing : I & A
researchProduct

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phas…

2018

IF 5.503 (2017); International audience; In preclinical models, IL-1β inhibition could enhance the efficacy of fluorouracil (5-FU). In this phase 2 study, we assessed the activity and safety of 5-FU plus bevacizumab and anakinra (an IL-1β and α inhibitor) in patients with metastatic colorectal (mCRC) refractory to chemotherapy and anti-angiogenic therapy. Eligible patients had unresectable mCRC; were refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy, and anti-EGFR therapy (for tumors with wild-type KRAS). Patients were treated with a simplified acid folinic plus 5-FU regimen and bevacizumab (5 mg/kg) both administered by intravenous infusion for 30 min…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyBevacizumabImmunologyPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerNeutropeniaGastroenterologyclicial trial optimizationlcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicinetherapeutic trialsImmunology and Allergyil1colorectalnew targetsAnakinrabusiness.industryclinical trialmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOxaliplatinIrinotecanRegimen030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesischemoimmunotherapymdscbusinesslcsh:RC581-607medicine.drugOncoimmunology
researchProduct

Cigarette Smoke Increases Endothelial CXCL16-Leukocyte CXCR6 Adhesion In Vitro and In Vivo. Potential Consequences in Chronic Obstructive Pulmonary D…

2017

Cardiovascular disease (CVD) is a major comorbidity in chronic obstructive pulmonary disease (COPD). Although the mechanism of its development remains largely unknown, it appears to be associated with cigarette consumption and reduced lung function. Therefore, the aim of this study was to investigate the potential link between water-soluble cigarette smoke extract (CSE)-induced endothelial dysfunction and the function of CXCL16/CXCR6 axis on the initial attachment of leukocytes, in addition to its possible impact on COPD-associated systemic inflammation. To do this, we employed several experimental approaches, including RNA silencing and flow cytometry analysis, the dynamic flow chamber tec…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyChemokinecardiovascular comorbidityImmunologychemokines030204 cardiovascular system & hematologySystemic inflammationPeripheral blood mononuclear cellendothelial dysfunctionchronic obstructive pulmonary disease03 medical and health sciences0302 clinical medicineInternal medicinemedicineImmunology and AllergyPlateletEndothelial dysfunctionCXCL16Original ResearchCOPDbiologybusiness.industrycigarette smokearterial endotheliumleukocyte recruitmentmedicine.disease030104 developmental biologyEndocrinologybiology.proteinmedicine.symptombusinesslcsh:RC581-607Intravital microscopyFrontiers in Immunology
researchProduct

Localized Interleukin-12 for Cancer Immunotherapy

2020

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable antitumor efficacy in preclinical models has yet to be replicated in humans. Early clinical trials in the mid-1990's showed that systemic delivery of IL-12 incurred dose-limiting toxicities. Nevertheless, IL-12's pleiotropic activity, i.e., its ability to engage multiple effector mechanisms and reverse tumor-induced immunosuppression, continues to entice cancer researchers. The development of strategies which maximize IL-12 delivery to the tumor microenvironment while minimizing systemic exposure are of increasing interest…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentDrug CompoundingImmunologyGenetic Vectorsinterleukin-12 (IL-12)Antineoplastic AgentsReviewBioinformatics03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsintratumoral administrationTumor MicroenvironmentImmunology and AllergyMedicineAnimalsHumansTumor microenvironmentDrug Carrierscancer immunotherapyAntitumor immunitybusiness.industryGene Transfer TechniquesCancerImmunotherapyGenetic Therapymedicine.diseaseInterleukin-12Clinical trialcytokine delivery system030104 developmental biologyTreatment OutcomeInterleukin 12Cancer vaccineImmunotherapybusinesslcsh:RC581-607cancer vaccinelocalized delivery030215 immunologyFrontiers in Immunology
researchProduct

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

2020

Autologous T cells engineered to express a chimeric antigen receptor (CAR) against the CD19 antigen are in the frontline of contemporary hemato-oncology therapies, leading to high remission rates in B-cell malignancies. Although effective, major obstacles involve the complex and costly individualized manufacturing process, and CD19 target antigen loss or modulation leading to resistant and relapse following CAR therapy. A potential solution for these limitations is the use of donor-derived γδT cells as a CAR backbone. γδT cells lack allogenecity and are safely used in haploidentical transplants. Moreover, γδT cells are known to mediate natural anti-tumor responses. Here, we describe a 14-da…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentImmunologyCell Culture TechniquesPriming (immunology)Mice SCIDImmunotherapy AdoptiveCD1903 medical and health sciencesMice0302 clinical medicineAntigenMice Inbred NODTransduction GeneticmedicineAnimalsHumansImmunology and Allergyimmuno oncologyB cell malignanciesOriginal ResearchLeukemiaReceptors Chimeric Antigenbiologychimeric antigen receptorChemistrygamma-delta T cellsReceptors Antigen T-Cell gamma-deltamedicine.diseaseXenograft Model Antitumor AssaysChimeric antigen receptorLeukemia030104 developmental biologyCytokinemedicine.anatomical_structureCell cultureCancer researchbiology.proteinBone marrowlcsh:RC581-607Genetic Engineering030215 immunologyFrontiers in Immunology
researchProduct

Novel Insight Into the Molecular and Metabolic Mechanisms Orchestrating IL-17 Production in γδ T Cells

2019

Increasing evidence has demonstrated that IL-17-producing γδ T cells (γδ T17) play a tumor-promoting role in a series of cancers via various mechanisms in mice and human cancers, though the relationship between γδ T17 and human tumors has yet to be extensively characterized and established. Molecular signals such as intrinsic cascade, environmental cues and cellular metabolic pathways including nutrient uptake and utilization in γδ T17 cells are significantly important for their activation, differentiation, and function. Understanding the molecular mechanisms and metabolic pathways of γδ T17 cells in both the physiological setting and tumor environment would contribute to the development of…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentMini ReviewMetabolic reprogrammingImmunologyBiology03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsmedicineTranscriptional regulationTumor MicroenvironmentImmunology and AllergyAnimalsHumansmetabolic reprogrammingtranscriptional regulationinnate immune cellsIntraepithelial Lymphocytescancer immunotherapyMicrobiotaInterleukin-17Immunotherapy3. Good healthCell biologyMetabolic pathway030104 developmental biologyInterleukin 17γδ T17 cellslcsh:RC581-607Function (biology)030215 immunologyFrontiers in Immunology
researchProduct

Transport of Amino Acids Across the Blood-Brain Barrier.

2020

The blood-brain-barrier (BBB), present in brain capillaries, constitutes an essential barrier mechanism for normal functioning and development of the brain. The presence of tight junctions between adjacent endothelial cells restricts permeability and movement of molecules between extracellular fluid and plasma. The protein complexes that control cell-cell attachment also polarize cellular membrane, so that it can be divided into luminal (blood-facing) and abluminal (brain) sides, and each solute that enters/leaves the brain must cross both membranes. Several amino acid (AA) transport systems with different distributions on both sides of the BBB have been described. In a broad sense, there a…

0301 basic medicineluminal membranePhysiologyfacilitative transportReviewBlood–brain barrierlcsh:Physiology03 medical and health sciences0302 clinical medicinePhysiology (medical)abluminal membraneCell polaritymedicineactive transportlcsh:QP1-981Tight junctionamino acid transportChemistryTransporterblood-brain barrierendothelial cellsEndothelial stem cellcell polarity030104 developmental biologymedicine.anatomical_structureMembraneBiophysicsEfflux030217 neurology & neurosurgeryHomeostasisFrontiers in physiology
researchProduct

Assessment of genetically modified maize NK603 x MON810 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐007)

2018

Efsa Panel On Genetically Modified Organisms (gmo)Scientific opinionRequestor:European Commission (DG SANTE)Question number:EFSA-Q-2017-00028; Following the submission of application EFSA-GMO-RX-007 under Regulation (EC) No 1829/2003 from Monsanto, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application of the herbicide-tolerant and insect-resistant genetically modified maize NK603 x MON810. The data received in the context of this renewal application contained post-market environmental monitoring reports, a systematic searc…

0301 basic medicinemaïsVeterinary (miscellaneous)gmo[SDV]Life Sciences [q-bio]2405 ParasitologyogmTP1-1185Plant SciencemaizeMicrobiologyzea mays03 medical and health sciences0404 agricultural biotechnology1110 Plant Sciencearticles 11 and 23TX341-6411106 Food ScienceNK603xMON8102. Zero hungerrenewal030109 nutrition & dieteticsNutrition. Foods and food supplymaize; NK603xMON810; renewal; articles 11 and 23; Regulation (EC) No1829/2003indian cornChemical technology2404 MicrobiologyRegulation (EC) No 1829/2003maize;NK603 x MON810;renewal;articles 11 and 23;Regulation (EC) No 1829/2003NK603 x MON81010079 Institute of Veterinary Pharmacology and Toxicology04 agricultural and veterinary sciences040401 food scienceSettore AGR/02 - Agronomia E Coltivazioni Erbacee3401 Veterinary (miscellaneous)Scientific OpinionSettore AGR/11 - Entomologia Generale E ApplicataRegulation (EC) No1829/2003570 Life sciences; biologyAnimal Science and ZoologyParasitology1103 Animal Science and ZoologyNK603 x MON810Regulation (EC) No 1829/2003Food Science
researchProduct

Minor environmental concentrations of antibiotics can modify bacterial virulence in co-infection with a non-targeted parasite.

2018

Leakage of medical residues into the environment can significantly impact natural communities. For example, antibiotic contamination from agriculture and aquaculture can directly influence targeted pathogens, but also other non-targeted taxa of commensals and parasites that regularly co-occur and co-infect the same host. Consequently, antibiotics could significantly alter interspecific interactions and epidemiology of the co-infecting parasite community. We studied how minor environmental concentrations of antibiotic affects the co-infection of two parasites, the bacterium Flavobacterium columnare and the fluke Diplostomum pseudospathaceum , in their fish host. We found that antibiotic in …

0301 basic medicinemedicine.drug_classAntibioticsVirulenceOxytetracyclineAquacultureTrematode InfectionsinfektiotFlavobacteriumantibioticsMicrobiologybakteerit03 medical and health sciencesFish DiseasesAntibiotic resistanceco-infectionAquacultureFlavobacteriaceae InfectionsloisetDrug Resistance BacterialmedicineWater Pollution ChemicalParasite hostingAnimalsbacteriabiologyVirulencebusiness.industryCoinfectionimumadotta1183antibiootitvirulenssiCommensalismbiology.organism_classificationAgricultural and Biological Sciences (miscellaneous)Anti-Bacterial Agents030104 developmental biology13. Climate actionympäristövaikutuksetOncorhynchus mykissFlavobacterium columnareparasiteta1181TrematodaGeneral Agricultural and Biological SciencesbusinessPathogen BiologyBacteriaBiology letters
researchProduct